Exelixis
#2129
Rank
$7.6B
Marketcap
United States
Country
Dr. Stelios Papadopoulos Ph.D. (Co-Founder & Independent Chair of the Board)
Dr. Michael M. Morrissey Ph.D. (CEO, Pres & Director)
Mr. Christopher J. Senner (Exec. VP & CFO)
Summary
History
Exelixis was founded in 1995 and went public in 2000. The company remains focused exclusively on cancer research, pioneering many new approaches to treating the disease and to developing targeted therapies. Over its history, Exelixis has obtained a number of breakthrough successes, including the discovery of its product portfolio, which includes medicines that are now being used to treat advanced cancers.
Key Team
Dr. Peter Lamb Ph.D. (Exec. VP of Scientific Strategy & Chief Scientific Officer)
Mr. Jeffrey J. Hessekiel J.D. (Exec. VP, Gen. Counsel & Sec.)
Mr. Patrick J. Haley M.B.A., MBA (Exec. VP of Commercial)
Dr. Dana T. Aftab Ph.D. (Exec. VP of Bus. Operations)
Ms. Susan T. Hubbard (Exec. VP of Public Affairs & Investor Relations)
Mr. Gregg Bernier (VP of Marketing)
Ms. Laura Dillard (Exec. VP of HR)
References
Dr. Stelios Papadopoulos Ph.D. (Co-Founder & Independent Chair of the Board)
Dr. Michael M. Morrissey Ph.D. (CEO, Pres & Director)
Mr. Christopher J. Senner (Exec. VP & CFO)